Daxor (DXR) AI Stock Analysis

• Market Cap: $35.03M
• Dividend Yield: N/A
• Average Volume (3M): 55.56K
• Price to Earnings (P/E): 30.3
• Beta (1Y): 0.41
• Revenue Growth: -97.00%
• EPS Growth: 3.43%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 4,962,245
• 10 Day Avg. Volume: 7,400
• 30 Day Avg. Volume: 55,558
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 63.64
• Enterprise Value/Gross Profit: 70.50
• Enterprise Value/Ebitda: -50.72
• 1Y Price Target: $22.00
• Price Target Upside: 98.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: ―

Daxor's stock score reflects a mixed performance. The strongest factor is the positive earnings call, showcasing significant revenue growth and strategic initiatives. However, financial performance is hindered by operational challenges and cash flow volatility. Technical analysis indicates a lack of strong momentum, and high valuation metrics suggest potential overvaluation.

Positive Factors

Acquisition Impact

Daxor's acquisition of exclusive rights to manufacture certain products is expected to be cash flow positive and accretive to earnings immediately.

FDA Approvals

Daxor's BVA diagnostic is the first FDA-approved system that provides direct blood volume measurements for patients.

Revenue Growth

The FDA clearance of the next-gen BVA positions Daxor to drive revenue growth and facilitate its transition to filing as an operating company, which should improve financial transparency and attract a broader investor base.

Sales Growth

Daxor's operating division delivered meaningful sales growth in the first half of the year, supported by increased utilization of single-use blood volume diagnostic kits, new account additions, and military contract revenue.

Negative Factors

Development Timeline

Daxor is developing a next-generation BVA that is more than three times faster and capable of providing full results at the bedside, with FDA approval expected in 2025.

Regulatory Strategy

The decision to pivot to a single 510(k) submission, rather than a dual CLIA waiver approach, is a prudent regulatory strategy that reduces data burden and accelerates the approval timeline.

Daxor Business Overview & Revenue Model

Company Description

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

How the Company Makes Money

Daxor Corporation generates revenue primarily through the sale and leasing of its proprietary blood volume analysis systems, such as the BVA-100. Additionally, the company earns income by providing related services, including testing and analysis of blood samples. This includes contracts with hospitals, clinics, and medical research institutions that utilize their technology for improved clinical decision-making. Daxor may also benefit from partnerships or collaborations with healthcare providers and research organizations that contribute to its growth and market reach. Factors such as regulatory approvals, technological advancements, and the increasing demand for precision in medical diagnostics play a significant role in its revenue generation.

Daxor Financial Statement Overview

Summary

Daxor demonstrates a mixed financial performance. The income statement highlights operational challenges despite recent profitability, with a notable improvement in net profit margin. The balance sheet is strong with no debt and a high equity ratio, suggesting financial stability. Cash flows are volatile but show signs of improvement, though converting income into cash remains a challenge.

Income Statement

Daxor's income statement shows a volatile revenue trajectory, with significant swings in total revenue from negative to positive figures over the years. The gross profit margin is strong at 100% for 2024, indicating that all revenue is gross profit, but a negative EBIT margin suggests high operational costs. The net profit margin improved from previous losses, highlighting recent profitability. However, the revenue growth rate is unstable, with a recent recovery in 2024.

Balance Sheet

The balance sheet reflects a robust equity position with a high equity ratio and no debt reported for 2024, indicating financial stability. Return on Equity (ROE) is positive, reinforcing profitability. The absence of debt lowers financial risk, but the company's ability to leverage for growth is limited. Asset growth is consistent, supporting long-term stability.

Cash Flow

Daxor's cash flow statement shows fluctuating free cash flow, with a positive shift in 2024. The operating cash flow to net income ratio is low, indicating potential challenges in converting income into cash. The free cash flow to net income ratio is also low, suggesting limited cash generation relative to reported profits. The overall cash flow trajectory is improving but remains volatile.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.13M	163.42K	6.31M	5.82M	-996.30K
Gross Profit	2.13M	163.42K	5.22M	4.82M	-1.68M
EBITDA	621.42K	329.74K	5.25M	4.75M	-1.72M
Net Income	536.33K	280.64K	5.18M	4.75M	-1.71M
Balance Sheet
Total Assets	36.63M	34.87M	30.26M	24.98M	16.55M
Cash, Cash Equivalents and Short-Term Investments	0.00	0.00	0.00	710.70K	617.80K
Total Debt	0.00	755.66K	1.23M	3.02M	170.69K
Total Liabilities	840.30K	858.76K	1.29M	3.83M	877.69K
Stockholders Equity	35.79M	34.01M	28.97M	21.15M	15.68M
Cash Flow
Free Cash Flow	25.69K	-3.66M	-769.30K	-2.76M	-2.45M
Operating Cash Flow	25.69K	-3.66M	-769.30K	-2.76M	-2.45M
Investing Cash Flow	0.00	2.75M	2.69M	74.76K	367.93K
Financing Cash Flow	-25.69K	3.66M	58.60K	2.85M	3.07M

Daxor Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Positive. The current price of 11.06 is above the 20-day moving average (MA) of 10.82, above the 50-day MA of 10.12, and above the 200-day MA of 8.62, indicating a bullish trend. The MACD of 0.27 indicates Positive momentum. The RSI at 55.59 is Neutral, neither overbought nor oversold. The STOCH value of 71.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DXR.

Daxor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	79 Outperform	$5.51B	47.23	8.60%	―	10.14%	0.04%
MHUA	62 Neutral	$11.80M	1.02	7.10%	―	-0.19%	-18.41%
PDEX	60 Neutral	$124.57M	14.15	26.60%	―	23.68%	341.25%
DXR	55 Neutral	$35.03M	30.33	5.26%	―	-97.00%	3.43%
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
FEMY	44 Neutral	$16.17M	―	-329.45%	―	98.61%	-1.98%
MLSS	40 Underperform	$48.48M	―	-123.50%	―	7.84%	-43.00%